Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.024
Y. Rourre , Q. Wynands , E. Desplanche , P.-E. Grillet , A. Virsolvy , A. Bourdin , O. Cazorla
Introduction
Quatrième cause de mortalité, la Bronchopneumopathie Chronique Obstructive (BPCO) présente 2 composantes : obstruction des voies aériennes distales et emphysème (élargissement des espaces aériens distaux dû à une destruction du parenchyme pulmonaire). À cet état chronique s’ajoutent des aggravations des symptômes appelées exacerbations, principalement secondaires à des infections. Les patients BPCO présentent de nombreuses comorbidités, notamment cardiaques, associées à un mauvais pronostic clinique. Notre équipe a développé un modèle animal d’emphysème exacerbé : rats « ELA-LPS », qui développent une insuffisance cardiaque à fraction d’éjection préservée (ICFEP, dysfonction diastolique) 5 semaines après l’exacerbation [1], comme en clinique. Les travaux ici exposés visent à réaliser différents degrés d’emphysème pour déterminer si les impacts cardiovasculaires sont dose-dépendants de l’emphysème.
Méthodes
L’emphysème est induit chez des rats mâles Wistar par instillation hebdomadaire d’élastase (ELA) pendant 4 semaines (doses de 4U, 6U ou 10U). Nous avons ajouté du lipopolysaccharide bactérien (LPS) lors de la dernière instillation pour simuler un stress infectieux et induire une exacerbation de la pathologie. Les rats ELA-LPS sont comparés à un groupe de rats contrôle, sans instillation. Les animaux sont euthanasiés 5 semaines après la dernière instillation.
L’emphysème pulmonaire a été évalué par histologie. Les propriétés cardiovasculaires ont été étudiées in-vivo : tension artérielle à la queue, échocardiographies et épreuves d’effort maximales cardiorespiratoires (VO2max, pour le retentissement général). L’hypothèse de l’hyperinflation pulmonaire statique a été testée en mesurant in-vivo la pression intrathoracique. La compliance pulmonaire a été mesurée ex-vivo.
Résultats
L’histologie confirme que notre procédure induit un emphysème dose-dépendant de l’élastase. Les rats ELA-LPS présentent une hypertension artérielle et une ICFEP (FEVG préservée, E/E’ augmenté…) corrélée au degré d’emphysème (R2 = 0,53, p = 0,0003). Ces anomalies se traduisent par une intolérance à l’effort lors des tests de VO2max. La mesure de compliance pulmonaire ex-vivo montre des altérations dose-dépendantes. La mesure in-vivo de pression intrathoracique est en cours d’analyse.
Conclusion
Notre procédure induit un emphysème dose-dépendant avec des conséquences vasculaires (hypertension artérielle), cardiaques (dysfonction diastolique dose-dépendante) et générales (intolérance à l’effort). Nous cherchons à présent à expliquer la pathogenèse de l’ICFEP via 2 hypothèses : hyperinflation pulmonaire statique (augmentation de la Capacité Résiduelle Fonctionnelle) et inflammation.
慢性阻塞性肺疾病(COPD)是第四大死亡原因,有两个组成部分:远气道阻塞和肺气肿(由于肺内膜破坏而导致的远气道扩张)。除了这种慢性疾病,症状的恶化被称为加重,主要是与感染有关的。慢性阻塞性肺病患者有多种并发疾病,包括心脏病,并伴有较差的临床预后。我们的团队开发了一个加重肺气肿的动物模型:“ELA-LPS”大鼠,它们在加重[1]5周后出现保守分数释放心力衰竭(ICFEP,舒张功能障碍),就像在临床中一样。本文的工作旨在进行不同程度的肺气肿,以确定心血管影响是否与肺气肿的剂量相关。肺气肿是由雄性大鼠Wistar每周注射弹性蛋白(ELA)引起的,持续4周(剂量为4U、6U或10U)。我们在最后一次注射中加入了细菌脂多糖(LPS),以模拟感染应激并诱导病理恶化。将ELA-LPS大鼠与未注射的对照组大鼠进行比较。动物在最后一次注射后5周被安乐死。肺气肿通过组织学进行评估。心血管特性在体内进行了研究:尾压、超声心动图和最大心肺压力(VO2max,用于一般回波)测试。通过测量体内胸腔内压力,验证了静态肺过度膨胀的假设。肺依从性是在体外测量的。结果组织学证实我们的程序引起剂量依赖性弹性松弛肺气肿。ELA-LPS大鼠有高血压和肺气肿程度相关的ICFEP (FEVG保存,E/E升高…)(R2 = 0.53, p = 0.0003)。在VO2max测试中,这些异常会导致努力不耐受。体外肺依从性测量显示剂量依赖性变化。目前正在分析体内胸腔内压力测量。结论我们的程序引起剂量依赖性肺气肿,并伴有血管(高血压)、心脏(剂量依赖性舒张功能障碍)和一般(压力不耐受)的后果。我们现在试图通过两个假设来解释ICFEP的发病机制:静态肺过度膨胀(剩余功能能力增加)和炎症。
{"title":"Impacts cardiovasculaires de l’emphysème exacerbé sur un modèle de rats adultes élastase-LPS","authors":"Y. Rourre , Q. Wynands , E. Desplanche , P.-E. Grillet , A. Virsolvy , A. Bourdin , O. Cazorla","doi":"10.1016/j.rmr.2025.02.024","DOIUrl":"10.1016/j.rmr.2025.02.024","url":null,"abstract":"<div><h3>Introduction</h3><div>Quatrième cause de mortalité, la Bronchopneumopathie Chronique Obstructive (BPCO) présente 2 composantes : obstruction des voies aériennes distales et emphysème (élargissement des espaces aériens distaux dû à une destruction du parenchyme pulmonaire). À cet état chronique s’ajoutent des aggravations des symptômes appelées exacerbations, principalement secondaires à des infections. Les patients BPCO présentent de nombreuses comorbidités, notamment cardiaques, associées à un mauvais pronostic clinique. Notre équipe a développé un modèle animal d’emphysème exacerbé : rats « ELA-LPS », qui développent une insuffisance cardiaque à fraction d’éjection préservée (ICFEP, dysfonction diastolique) 5 semaines après l’exacerbation <span><span>[1]</span></span>, comme en clinique. Les travaux ici exposés visent à réaliser différents degrés d’emphysème pour déterminer si les impacts cardiovasculaires sont dose-dépendants de l’emphysème.</div></div><div><h3>Méthodes</h3><div>L’emphysème est induit chez des rats mâles Wistar par instillation hebdomadaire d’élastase (ELA) pendant 4 semaines (doses de 4U, 6U ou 10U). Nous avons ajouté du lipopolysaccharide bactérien (LPS) lors de la dernière instillation pour simuler un stress infectieux et induire une exacerbation de la pathologie. Les rats ELA-LPS sont comparés à un groupe de rats contrôle, sans instillation. Les animaux sont euthanasiés 5 semaines après la dernière instillation.</div><div>L’emphysème pulmonaire a été évalué par histologie. Les propriétés cardiovasculaires ont été étudiées <em>in-vivo</em> : tension artérielle à la queue, échocardiographies et épreuves d’effort maximales cardiorespiratoires (VO<sub>2</sub>max, pour le retentissement général). L’hypothèse de l’hyperinflation pulmonaire statique a été testée en mesurant <em>in-vivo</em> la pression intrathoracique. La compliance pulmonaire a été mesurée <em>ex-vivo</em>.</div></div><div><h3>Résultats</h3><div>L’histologie confirme que notre procédure induit un emphysème dose-dépendant de l’élastase. Les rats ELA-LPS présentent une hypertension artérielle et une ICFEP (FEVG préservée, E/E’ augmenté…) corrélée au degré d’emphysème (R<sup>2</sup> <!-->=<!--> <!-->0,53, <em>p</em> <!-->=<!--> <!-->0,0003). Ces anomalies se traduisent par une intolérance à l’effort lors des tests de VO<sub>2</sub>max. La mesure de compliance pulmonaire <em>ex-vivo</em> montre des altérations dose-dépendantes. La mesure <em>in-vivo</em> de pression intrathoracique est en cours d’analyse.</div></div><div><h3>Conclusion</h3><div>Notre procédure induit un emphysème dose-dépendant avec des conséquences vasculaires (hypertension artérielle), cardiaques (dysfonction diastolique dose-dépendante) et générales (intolérance à l’effort). Nous cherchons à présent à expliquer la pathogenèse de l’ICFEP <em>via</em> 2 hypothèses : hyperinflation pulmonaire statique (augmentation de la Capacité Résiduelle Fonctionnelle) et inflammation.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 193"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.076
A. Curioni, D. Pokhreal, G.D. Helou
Idiopathic pulmonary fibrosis (IPF) is a lethal interstitial lung disease with a high mortality rate. The mechanisms behind the pathophysiology of IPF development remain poorly understood. However, recent developments in fundamental and translational studies demonstrate that immune cells play a significant regulatory role in IPF. Immune players generate multiple growth factors and mediators that greatly affect the initiation and progression of IPF. Immune checkpoints are known for their capacity to regulate the intensity of immune responses. Our project aims to study the implications of these receptors in IPF. Based on a transcriptomic approach, we did identify the most relevant receptors in lung immune cells from IPF patients. Flow cytometry analyses are used to compare the expression of the identified receptors between IPF patients and healthy donors in a stratification approach. Ex-vivo experiments are also implemented to understand how the inhibition or overexpression of these receptors can impact the profibrotic activity of immune cells. In parallel, several models of transgenic mice are currently generated to investigate the implication of the identified receptors in the development of pulmonary fibrosis. Overall, this project might have the potential to uncover novel immune mechanisms leading to new diagnostic and therapeutic tools against a fatal disease.
{"title":"The therapeutic potential of targeting immune checkpoints in IPF","authors":"A. Curioni, D. Pokhreal, G.D. Helou","doi":"10.1016/j.rmr.2025.02.076","DOIUrl":"10.1016/j.rmr.2025.02.076","url":null,"abstract":"<div><div>Idiopathic pulmonary fibrosis (IPF) is a lethal interstitial lung disease with a high mortality rate. The mechanisms behind the pathophysiology of IPF development remain poorly understood. However, recent developments in fundamental and translational studies demonstrate that immune cells play a significant regulatory role in IPF. Immune players generate multiple growth factors and mediators that greatly affect the initiation and progression of IPF. Immune checkpoints are known for their capacity to regulate the intensity of immune responses. Our project aims to study the implications of these receptors in IPF. Based on a transcriptomic approach, we did identify the most relevant receptors in lung immune cells from IPF patients. Flow cytometry analyses are used to compare the expression of the identified receptors between IPF patients and healthy donors in a stratification approach. Ex-vivo experiments are also implemented to understand how the inhibition or overexpression of these receptors can impact the profibrotic activity of immune cells. In parallel, several models of transgenic mice are currently generated to investigate the implication of the identified receptors in the development of pulmonary fibrosis. Overall, this project might have the potential to uncover novel immune mechanisms leading to new diagnostic and therapeutic tools against a fatal disease.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 219"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.017
J. Jacquet , E. Marcos , L. Lipskaia , V. Gros , E. Born , N. Vienney , A. Houssaini , M. Goekyildirim , L. Boyer , S. Adnot
<div><div>Senescent endothelial cells (ECs) represent 30 to 50 % of senescent lung cells during aging and/or development of several lung diseases, including pulmonary hypertension (PH) (Born E et al, Circulation 2023) and emphysema. One potential mechanism is impaired angiogenic vascular endothelial growth factor (VEGF) signalling due to increased production of the soluble form of VEGF receptor 1 (sVEGFR1) via alternative splicing of VEGFR1. sVEGFR1 then acts as a VEGF trap.</div><div>The objective is to evaluate the role of impaired VEGF signalling in pulmonary EC senescence during aging and the development of PH and emphysema.</div><div>To characterize the lung expression of sVEGFR1 and VEGF receptors in the lung endothelial cells of young and old patients (classified as emphysematous and controls) undergoing lung surgery, 90 patients will be included during the candidate PhD.</div><div>In parallel, the lung expression of sVEGFR1 and VEGF receptors will be assessed in young and old mice [developing moderate emphysema and PAH], as well as in mouse models of PH (exposure to chronic hypoxia combined to SUGEN) and emphysema (elastase, elastin± mice), and mice with elimination of senescent cells (ABT senolytic treatment), linked to the rarefaction of the pulmonary capillary network (ICAM-1/CD<sub>31</sub>labelling) and the accumulation of senescent ECs (measurement of senescence and DNA damage markers p16, p21).</div><div>To counter EC senescence during aging and PH development, we generated a new mouse model overexpressing VEGF via a constitutive or tissue-specific inducible system allowing controlled delivery of VEGF from the liver to the lungs (VEGF-TG mice).</div><div>The lungs of aged mice compared to young mice have lower capillary density, manifested by a reduction in the number of ECs stained for ICAM1. Treatment of mice with the VEGF receptor inhibitor Sugen amplifies these effects and increases the number of p16-marked senescent ECs, thereby reducing the pulmonary capillary network, impairing pulmonary hemodynamics, and inducing emphysema. Lung expression of sVEGFR1 in mice developing hypoxic PH is increased and worsened by Sugen.</div><div>We show in vitro that sVEGFR1 treatment of cultured ECs from patients leads to cellular senescence. Conversely, VEGF treatment reduces endothelial cell senescence and improves proliferation. Senescent endothelial cells produce less sVEGFR1 in both controls and lung emphysema patients. Emphysema patients show higher EC senescence with higher p16 RNA level and B-galactosidase stained cells. ECs from emphysema patients show a lower cumulative PDL level than control patients. Furthermore, in both control and emphysema patients, there is a tendency towards decreased VEGFR1/2 and sVEGFR1 RNA expression in senescent ECs.</div><div>The results obtained in old VEGF-TG mice show the preservation of pulmonary microvascular density as well as the suppression of p16-stained cells and protection against pulmonary emp
{"title":"Counteracting pulmonary vascular endothelial cell senescence to combat age-related lung dysfunction and pulmonary hypertension","authors":"J. Jacquet , E. Marcos , L. Lipskaia , V. Gros , E. Born , N. Vienney , A. Houssaini , M. Goekyildirim , L. Boyer , S. Adnot","doi":"10.1016/j.rmr.2025.02.017","DOIUrl":"10.1016/j.rmr.2025.02.017","url":null,"abstract":"<div><div>Senescent endothelial cells (ECs) represent 30 to 50 % of senescent lung cells during aging and/or development of several lung diseases, including pulmonary hypertension (PH) (Born E et al, Circulation 2023) and emphysema. One potential mechanism is impaired angiogenic vascular endothelial growth factor (VEGF) signalling due to increased production of the soluble form of VEGF receptor 1 (sVEGFR1) via alternative splicing of VEGFR1. sVEGFR1 then acts as a VEGF trap.</div><div>The objective is to evaluate the role of impaired VEGF signalling in pulmonary EC senescence during aging and the development of PH and emphysema.</div><div>To characterize the lung expression of sVEGFR1 and VEGF receptors in the lung endothelial cells of young and old patients (classified as emphysematous and controls) undergoing lung surgery, 90 patients will be included during the candidate PhD.</div><div>In parallel, the lung expression of sVEGFR1 and VEGF receptors will be assessed in young and old mice [developing moderate emphysema and PAH], as well as in mouse models of PH (exposure to chronic hypoxia combined to SUGEN) and emphysema (elastase, elastin± mice), and mice with elimination of senescent cells (ABT senolytic treatment), linked to the rarefaction of the pulmonary capillary network (ICAM-1/CD<sub>31</sub>labelling) and the accumulation of senescent ECs (measurement of senescence and DNA damage markers p16, p21).</div><div>To counter EC senescence during aging and PH development, we generated a new mouse model overexpressing VEGF via a constitutive or tissue-specific inducible system allowing controlled delivery of VEGF from the liver to the lungs (VEGF-TG mice).</div><div>The lungs of aged mice compared to young mice have lower capillary density, manifested by a reduction in the number of ECs stained for ICAM1. Treatment of mice with the VEGF receptor inhibitor Sugen amplifies these effects and increases the number of p16-marked senescent ECs, thereby reducing the pulmonary capillary network, impairing pulmonary hemodynamics, and inducing emphysema. Lung expression of sVEGFR1 in mice developing hypoxic PH is increased and worsened by Sugen.</div><div>We show in vitro that sVEGFR1 treatment of cultured ECs from patients leads to cellular senescence. Conversely, VEGF treatment reduces endothelial cell senescence and improves proliferation. Senescent endothelial cells produce less sVEGFR1 in both controls and lung emphysema patients. Emphysema patients show higher EC senescence with higher p16 RNA level and B-galactosidase stained cells. ECs from emphysema patients show a lower cumulative PDL level than control patients. Furthermore, in both control and emphysema patients, there is a tendency towards decreased VEGFR1/2 and sVEGFR1 RNA expression in senescent ECs.</div><div>The results obtained in old VEGF-TG mice show the preservation of pulmonary microvascular density as well as the suppression of p16-stained cells and protection against pulmonary emp","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 190"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.054
M. Brollo , Q. Marquant , M. Dres , H. Salvator , J. Cohen , E. Sage , M. Glorion , S. Grassin-Delyle , P. Devillier
<div><h3>Introduction</h3><div>COPD affects approximately 10% of the global population, with three million annual deaths. About half of COPD cases are linked to smoking, but fewer than 50% of heavy smokers develop the disease. The pharmacoloical treatment of stable COPD relies on inhaled bronchodilators and corticosteroids (ICS). The ICS use benefit in terms of lung function and exacerbation rates to both current and ex-smokers with COPD although the magnitude of the effect is lower in heavy or current smokers compared to light or ex-smokers. Cigarette smoke (CS), rich in free radicals, increases immune cells recruitment in the lungs, particularly alveolar macrophages (AM) <span><span>[1]</span></span>. Studies show varied results on the production of pro-inflammatory cytokines by AMs in smokers vs. ex- or non-smokers. Moreover, there is also a large variation in the therapeutic response to ICS in COPD patients. The lack of clear data prevents an objective view of the impact of CS on AM activation and their sensitivity to corticosteroids. This study evaluates the inflammatory responses induced by cigarette smoke extracts (CSE) on human lung macrophages in vitro and compares the effect of budesonide (BUD) under conditions exposed to CSE or LPS.</div></div><div><h3>Methods</h3><div>Lung tissues were obtained from 51 patients undergoing surgical resection for lung cancer. Peripheral tissues distant from the tumor were carefully dissected. Lung macrophages (LM) were isolated through cell adhesion from the peripheral tissue supernatant <span><span>[2]</span></span>, while parenchymal explants (PE) were prepared by dissecting 50<!--> <!-->mg fragments from the lung tissues. LM and PE were cultured separately in a warm medium containing cigarette smoke extract (CSE) at concentrations of 1%, 5%, and 7.5% for 24<!--> <!-->hours. In some experiments, LPS (10<!--> <!-->ng/mL for LM, 1<!--> <!-->μg/mL for PE) or TNF-α (10<!--> <!-->ng/mL) was added to the culture one hour after CSE stimulation. Additionally, in certain conditions, LM or PE stimulated with CSE were pre-incubated with BUD at concentrations of 10<sup>−10</sup>, 10<sup>−9</sup>, and 10<sup>−8</sup> <!-->M for 30<!--> <!-->minutes before LPS stimulation. After 24<!--> <!-->hours, supernatants were collected, and cytokine production (TNF-α, IL-6, CCL2, CCL4, CXCL1, CXCL5, and CXCL8) was measured in the LM and PE supernatants using ELISA.</div></div><div><h3>Results</h3><div>Our results show that CSE, both with and without stimulation by LPS or TNF-α, modulates the production of pro-inflammatory cytokines such as TNF-α, IL-6, CCL2, CCL4, CXCL1, CXCL5, and CXCL8 in LM. In contrast, these treatments did not have significant effects on cytokine production in the PE model. Additionally, we observed that the maximum release of pro-inflammatory cytokines by LM was higher when treated with both CSE and BUD compared to treatment with LPS and BUD.</div></div><div><h3>Conclusion</h3><div>This study has enhan
{"title":"Difference in the inflammatory response and the corticoid response of human lung macrophages and parenchymal explants to ex-vivo cigarette smoke exposure","authors":"M. Brollo , Q. Marquant , M. Dres , H. Salvator , J. Cohen , E. Sage , M. Glorion , S. Grassin-Delyle , P. Devillier","doi":"10.1016/j.rmr.2025.02.054","DOIUrl":"10.1016/j.rmr.2025.02.054","url":null,"abstract":"<div><h3>Introduction</h3><div>COPD affects approximately 10% of the global population, with three million annual deaths. About half of COPD cases are linked to smoking, but fewer than 50% of heavy smokers develop the disease. The pharmacoloical treatment of stable COPD relies on inhaled bronchodilators and corticosteroids (ICS). The ICS use benefit in terms of lung function and exacerbation rates to both current and ex-smokers with COPD although the magnitude of the effect is lower in heavy or current smokers compared to light or ex-smokers. Cigarette smoke (CS), rich in free radicals, increases immune cells recruitment in the lungs, particularly alveolar macrophages (AM) <span><span>[1]</span></span>. Studies show varied results on the production of pro-inflammatory cytokines by AMs in smokers vs. ex- or non-smokers. Moreover, there is also a large variation in the therapeutic response to ICS in COPD patients. The lack of clear data prevents an objective view of the impact of CS on AM activation and their sensitivity to corticosteroids. This study evaluates the inflammatory responses induced by cigarette smoke extracts (CSE) on human lung macrophages in vitro and compares the effect of budesonide (BUD) under conditions exposed to CSE or LPS.</div></div><div><h3>Methods</h3><div>Lung tissues were obtained from 51 patients undergoing surgical resection for lung cancer. Peripheral tissues distant from the tumor were carefully dissected. Lung macrophages (LM) were isolated through cell adhesion from the peripheral tissue supernatant <span><span>[2]</span></span>, while parenchymal explants (PE) were prepared by dissecting 50<!--> <!-->mg fragments from the lung tissues. LM and PE were cultured separately in a warm medium containing cigarette smoke extract (CSE) at concentrations of 1%, 5%, and 7.5% for 24<!--> <!-->hours. In some experiments, LPS (10<!--> <!-->ng/mL for LM, 1<!--> <!-->μg/mL for PE) or TNF-α (10<!--> <!-->ng/mL) was added to the culture one hour after CSE stimulation. Additionally, in certain conditions, LM or PE stimulated with CSE were pre-incubated with BUD at concentrations of 10<sup>−10</sup>, 10<sup>−9</sup>, and 10<sup>−8</sup> <!-->M for 30<!--> <!-->minutes before LPS stimulation. After 24<!--> <!-->hours, supernatants were collected, and cytokine production (TNF-α, IL-6, CCL2, CCL4, CXCL1, CXCL5, and CXCL8) was measured in the LM and PE supernatants using ELISA.</div></div><div><h3>Results</h3><div>Our results show that CSE, both with and without stimulation by LPS or TNF-α, modulates the production of pro-inflammatory cytokines such as TNF-α, IL-6, CCL2, CCL4, CXCL1, CXCL5, and CXCL8 in LM. In contrast, these treatments did not have significant effects on cytokine production in the PE model. Additionally, we observed that the maximum release of pro-inflammatory cytokines by LM was higher when treated with both CSE and BUD compared to treatment with LPS and BUD.</div></div><div><h3>Conclusion</h3><div>This study has enhan","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Pages 208-209"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.077
A. Lebeau , N. Worbe , M. Brollo , H. Salvator , P. Devillier , A. Magnan , C. Tchérakian , Q. Marquant
Introduction
Les pneumopathies interstitielles diffuses (PID) sont des pathologies rares d’étiologies variées menant pour la plupart à la fibrose pulmonaire. Sur une cohorte de 220 atteints de PID fibrosantes suivis à l’hôpital Foch, 58 présentaient un taux de polynucléaires à éosinophiles (PNE) sanguin ≥ 0,3 g/L considéré comme élevé [1]. Bien que le rôle des PNE dans le développement et/ou l’exacerbation des PID ait été fortement suggéré [2], il n’a jamais été démontré. Nous émettons l’hypothèse que les PNE jouent un rôle dans la physiopathologie des PID. Ici, nous montrons in vitro que, selon leur statut d’activation, les PNE sont capables d’induire une transition épithélio-mésenchymateuse (TEM) sur les cellules épithéliales respiratoires.
Méthodes
Les PNE ont été isolés du sang de volontaires sains puis mis en coculture, après vérification de leur pureté par cytométrie en flux (90 %), avec des lignées épithéliales bronchiques et alvéolaires (respectivement les cellules BEAS-2B et A549) et des cellules épithéliales bronchiques (CEB) primaires issues de donneurs sains. Les cytokines pro-inflammatoires (IL-6, CCL2 et CCL5) et les marqueurs de la TEM (MMP9, TGFß, Fibronectine et Vimentine) ont été mesurés par ELISA et WB.
Résultats
La présence des PNE provoque une inflammation sur tous les types de cellules épithéliales respiratoires étudiés via une augmentation de la sécrétion d’IL-6, CCL2 et CCL5 par rapport à la condition contrôle sans PNE. Les PNE provoquent également une augmentation de MMP9, TGFb, Fibronectine et de Vimentine sur les cellules BEAS 2B et CEB mais pas sur les cellules A549.
Conclusion
Cette étude décrit la mise au point de la coculture de PNE avec des lignées cellulaires et des cellules primaires respiratoires. Ce modèle nous a permis d’identifier un effet pro-inflammatoire des PNE sur les cellules épithéliales respiratoires ainsi qu’une apparition des marqueurs de la TEM sur les cellules bronchiques. Dans ce contexte, il est possible que les PNE puissent constituer une caractéristique traitable pour les patients atteints de PID présentant une éosinophilie sanguine ≥ 0,3 g/L.
{"title":"Les éosinophiles humains participent à la transition épithélio-mésenchymateuse des cellules épithéliales respiratoires","authors":"A. Lebeau , N. Worbe , M. Brollo , H. Salvator , P. Devillier , A. Magnan , C. Tchérakian , Q. Marquant","doi":"10.1016/j.rmr.2025.02.077","DOIUrl":"10.1016/j.rmr.2025.02.077","url":null,"abstract":"<div><h3>Introduction</h3><div>Les pneumopathies interstitielles diffuses (PID) sont des pathologies rares d’étiologies variées menant pour la plupart à la fibrose pulmonaire. Sur une cohorte de 220 atteints de PID fibrosantes suivis à l’hôpital Foch, 58 présentaient un taux de polynucléaires à éosinophiles (PNE) sanguin ≥<!--> <!-->0,3<!--> <!-->g/L considéré comme élevé <span><span>[1]</span></span>. Bien que le rôle des PNE dans le développement et/ou l’exacerbation des PID ait été fortement suggéré <span><span>[2]</span></span>, il n’a jamais été démontré. Nous émettons l’hypothèse que les PNE jouent un rôle dans la physiopathologie des PID. Ici, nous montrons in vitro que, selon leur statut d’activation, les PNE sont capables d’induire une transition épithélio-mésenchymateuse (TEM) sur les cellules épithéliales respiratoires.</div></div><div><h3>Méthodes</h3><div>Les PNE ont été isolés du sang de volontaires sains puis mis en coculture, après vérification de leur pureté par cytométrie en flux (90 %), avec des lignées épithéliales bronchiques et alvéolaires (respectivement les cellules BEAS-2B et A549) et des cellules épithéliales bronchiques (CEB) primaires issues de donneurs sains. Les cytokines pro-inflammatoires (IL-6, CCL2 et CCL5) et les marqueurs de la TEM (MMP9, TGFß, Fibronectine et Vimentine) ont été mesurés par ELISA et WB.</div></div><div><h3>Résultats</h3><div>La présence des PNE provoque une inflammation sur tous les types de cellules épithéliales respiratoires étudiés via une augmentation de la sécrétion d’IL-6, CCL2 et CCL5 par rapport à la condition contrôle sans PNE. Les PNE provoquent également une augmentation de MMP9, TGFb, Fibronectine et de Vimentine sur les cellules BEAS 2B et CEB mais pas sur les cellules A549.</div></div><div><h3>Conclusion</h3><div>Cette étude décrit la mise au point de la coculture de PNE avec des lignées cellulaires et des cellules primaires respiratoires. Ce modèle nous a permis d’identifier un effet pro-inflammatoire des PNE sur les cellules épithéliales respiratoires ainsi qu’une apparition des marqueurs de la TEM sur les cellules bronchiques. Dans ce contexte, il est possible que les PNE puissent constituer une caractéristique traitable pour les patients atteints de PID présentant une éosinophilie sanguine ≥<!--> <!-->0,3<!--> <!-->g/L.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 220"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.064
G. Pamart, O. Le Rouzic, M. Pichavant, P. Gosset, O. Poulain-Godefroy
Introduction
La bronchopneumopathie chronique obstructive (BPCO) se caractérise par une inflammation chronique et une obstruction des voies respiratoires principalement dues à l’exposition au tabac. Les patients atteints de BPCO développent fréquemment des exacerbations principalement causées par des infections, souvent virales, associées à une inflammation pulmonaire, une progression de la maladie et une augmentation de la mortalité. La voie métabolique du tryptophane, permettant la formation de NAD (Nicotinamide Adénine Dinucléotide) est également affectée par la fumée de cigarette (CS) entraînant une modification de la production de l’acide quinolinique (QA), un métabolite possédant des propriétés immunomodulatrices dont les taux sont altérés chez les patients atteints de BPCO.
Méthode
Notre objectif est de déterminer le rôle potentiel de la voie du tryptophane, et plus particulièrement de QA, au cours des exacerbations de la BPCO. La production de QA et l’expression des enzymes de la voie des kynurénines ont été mesurées chez des souris C57Bl6 après une semaine d’infection par le virus de la grippe H3N2 (MOI 0,5). Des cellules épithéliales bronchiques (BEAS 2B) et des macrophages humains ont également été exposés à QA (100 μM) 1 heure avant une infection par H3N2. Les réponses antivirales et inflammatoires ont été évaluées 6 et 24 heures après l’infection par RT-qPCR et dosage ELISA des cytokines.
Résultats
L’infection virale a stimulé l’expression de certaines enzymes de la voie des kynurénines 24 h après l’infection viral, et à augmenter la concentration de QA au sein du tissu pulmonaire. La préexposition à QA augmente l’expression génique de molécules antivirales telles que IFNb et Mx1 24 heures après l’infection dans les cellules BEAS 2B mais à moduler la réponse antivirale dans les macrophages en stimulant l’IFNb, mais en diminuant l’expression des récepteurs TLR. QA a également modulé l’inflammation des macrophages en stimulant l’expression et la sécrétion de molécules telles que IL6, IL8, TNFa ou encore CXCL1.
Conclusion
L’infection grippale induit la voie des kynurénines, et augmente la concentration de l’acide quinolinique, qui semble impacter la réponse inflammatoire et antivirale de l’épithélium respiratoire et des macrophages, suggérant son rôle au cours des exacerbations de la BPCO.
{"title":"Impact of cigarette smoke on inflammatory effect of Quinolinic acid during influenza infection","authors":"G. Pamart, O. Le Rouzic, M. Pichavant, P. Gosset, O. Poulain-Godefroy","doi":"10.1016/j.rmr.2025.02.064","DOIUrl":"10.1016/j.rmr.2025.02.064","url":null,"abstract":"<div><h3>Introduction</h3><div>La bronchopneumopathie chronique obstructive (BPCO) se caractérise par une inflammation chronique et une obstruction des voies respiratoires principalement dues à l’exposition au tabac. Les patients atteints de BPCO développent fréquemment des exacerbations principalement causées par des infections, souvent virales, associées à une inflammation pulmonaire, une progression de la maladie et une augmentation de la mortalité. La voie métabolique du tryptophane, permettant la formation de NAD (Nicotinamide Adénine Dinucléotide) est également affectée par la fumée de cigarette (CS) entraînant une modification de la production de l’acide quinolinique (QA), un métabolite possédant des propriétés immunomodulatrices dont les taux sont altérés chez les patients atteints de BPCO.</div></div><div><h3>Méthode</h3><div>Notre objectif est de déterminer le rôle potentiel de la voie du tryptophane, et plus particulièrement de QA, au cours des exacerbations de la BPCO. La production de QA et l’expression des enzymes de la voie des kynurénines ont été mesurées chez des souris C57Bl6 après une semaine d’infection par le virus de la grippe H<sub>3</sub>N2 (MOI 0,5). Des cellules épithéliales bronchiques (BEAS 2B) et des macrophages humains ont également été exposés à QA (100<!--> <!-->μM) 1 heure avant une infection par H<sub>3</sub>N2. Les réponses antivirales et inflammatoires ont été évaluées 6 et 24<!--> <!-->heures après l’infection par RT-qPCR et dosage ELISA des cytokines.</div></div><div><h3>Résultats</h3><div>L’infection virale a stimulé l’expression de certaines enzymes de la voie des kynurénines 24<!--> <!-->h après l’infection viral, et à augmenter la concentration de QA au sein du tissu pulmonaire. La préexposition à QA augmente l’expression génique de molécules antivirales telles que IFNb et Mx1 24<!--> <!-->heures après l’infection dans les cellules BEAS 2B mais à moduler la réponse antivirale dans les macrophages en stimulant l’IFNb, mais en diminuant l’expression des récepteurs TLR. QA a également modulé l’inflammation des macrophages en stimulant l’expression et la sécrétion de molécules telles que IL6, IL8, TNFa ou encore CXCL1.</div></div><div><h3>Conclusion</h3><div>L’infection grippale induit la voie des kynurénines, et augmente la concentration de l’acide quinolinique, qui semble impacter la réponse inflammatoire et antivirale de l’épithélium respiratoire et des macrophages, suggérant son rôle au cours des exacerbations de la BPCO.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 213"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.055
Y. Colombani, P.E. Grillet, Y. Rourre, Q. Wynands, C. Roure, L. Alburquerque, F. Lopez, P. Pomies, E. Passerieux, A. Bourdin, O. Cazorla
Introduction
Chronic Obstructive Pulmonary Disease (COPD), is marked by chronic airflow limitation due to small airway obstruction and emphysema, which involves abnormal enlargement of lung air spaces and inflammation-induced tissue destruction. COPD often coexists with cardiovascular diseases, likely due to chronic inflammation. As an age-related disease, COPD's effects are worsened with aging, intensifying both lung and systemic impacts. However, the connection between age-related emphysema and cardiac issues remains unclear, indicating a need for more research on how aging affects COPD's impact on cardiovascular health.
Methods
Old male Wistar rats (18 months old, n = 9 control, 5 ELA-LPS) received weekly intra-tracheal instillations of elastase (ELA) over 4 weeks at a dose of 10 U. I to induce emphysema. In the fourth week, alongside elastase, bacterial lipopolysaccharide (LPS) derived from E.coli O55 B: 5 was delivered to mimic a bacterial exacerbation. We evaluated pulmonary, cardiac and muscular functions using various in-vivo and ex-vivo methods, including cardiorespiratory tests on a treadmill, whole-body plethysmography and echocardiography. The results in aged animals were compared with those from young animals (6–7 weeks-old).
Results
Preliminary results revealed significant alteration in cardiac systolic function, along by morphological changes in the left ventricular posterior wall during systole and diastole, compared to the young emphysema model, where a correlation between emphysema and diastolic dysfunction was noted. Unexpectedly, there was a trend of improvement in respiratory parameters, including Peak Inspiratory Flow, Peak Expiratory Flow, and tidal volume. The cardiorespiratory performance test showed a trend towards reduced O2 consumption and decreased exercise capacity, consistent with aging patterns. Then, the assessment of lung elastic properties (ex vivo pressure-volume curve) indicated a greater loss of pulmonary elasticity compared to the young emphysematous model. Additionally, ex vivo endurance and force tests on the soleus muscle showed a tendency toward reduced muscle endurance and strength, aligning with the findings from the treadmill test.
Conclusion
This multidisciplinary approach seeks to deepen our understanding of the age-related aspects of COPD-emphysema and its broader impact on human health. Initial results are promising, showing that aged rats exhibit a more severe phenotype than younger ones. Once confirmed, the underlying causes of these age-related dysfunctions compared to younger animals need to be determined to provide valuable insights into associated cardiac disorders.
{"title":"Consequences of exacerbation in old rats with emphysema","authors":"Y. Colombani, P.E. Grillet, Y. Rourre, Q. Wynands, C. Roure, L. Alburquerque, F. Lopez, P. Pomies, E. Passerieux, A. Bourdin, O. Cazorla","doi":"10.1016/j.rmr.2025.02.055","DOIUrl":"10.1016/j.rmr.2025.02.055","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic Obstructive Pulmonary Disease (COPD), is marked by chronic airflow limitation due to small airway obstruction and emphysema, which involves abnormal enlargement of lung air spaces and inflammation-induced tissue destruction. COPD often coexists with cardiovascular diseases, likely due to chronic inflammation. As an age-related disease, COPD's effects are worsened with aging, intensifying both lung and systemic impacts. However, the connection between age-related emphysema and cardiac issues remains unclear, indicating a need for more research on how aging affects COPD's impact on cardiovascular health.</div></div><div><h3>Methods</h3><div>Old male Wistar rats (18 months old, <em>n</em> <!-->=<!--> <!-->9 control, 5 ELA-LPS) received weekly intra-tracheal instillations of elastase (ELA) over 4 weeks at a dose of 10<!--> <!-->U. I to induce emphysema. In the fourth week, alongside elastase, bacterial lipopolysaccharide (LPS) derived from <em>E.</em> <em>coli</em> O55 B: 5 was delivered to mimic a bacterial exacerbation. We evaluated pulmonary, cardiac and muscular functions using various in-vivo and ex-vivo methods, including cardiorespiratory tests on a treadmill, whole-body plethysmography and echocardiography. The results in aged animals were compared with those from young animals (6–7 weeks-old).</div></div><div><h3>Results</h3><div>Preliminary results revealed significant alteration in cardiac systolic function, along by morphological changes in the left ventricular posterior wall during systole and diastole, compared to the young emphysema model, where a correlation between emphysema and diastolic dysfunction was noted. Unexpectedly, there was a trend of improvement in respiratory parameters, including Peak Inspiratory Flow, Peak Expiratory Flow, and tidal volume. The cardiorespiratory performance test showed a trend towards reduced O<sub>2</sub> consumption and decreased exercise capacity, consistent with aging patterns. Then, the assessment of lung elastic properties (ex vivo pressure-volume curve) indicated a greater loss of pulmonary elasticity compared to the young emphysematous model. Additionally, ex vivo endurance and force tests on the soleus muscle showed a tendency toward reduced muscle endurance and strength, aligning with the findings from the treadmill test.</div></div><div><h3>Conclusion</h3><div>This multidisciplinary approach seeks to deepen our understanding of the age-related aspects of COPD-emphysema and its broader impact on human health. Initial results are promising, showing that aged rats exhibit a more severe phenotype than younger ones. Once confirmed, the underlying causes of these age-related dysfunctions compared to younger animals need to be determined to provide valuable insights into associated cardiac disorders.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 209"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.049
F. Lepretre , L. Moreno , A. Joshkon , N. Bardin , M. Blot-Chabaud , P. Chanez , D. Gras
Introduction
Asthma is a chronic lung disease affecting 300 million people worldwide, 2-10 % of whom suffer from severe asthma. In asthma, the bronchial epithelium is dysregulated, contributing to the pathophysiology of the disease. CD146 is an adhesion molecule that is highly expressed on all the cells from the vascular system, including endothelial cells. It is also expressed by epithelial cells, but its functions in these cells are poorly understood, as is its role in severe asthma. The aim of our study is to elucidate the role of CD146 in the bronchial epithelium and its implication in severe asthma.
Methods
Bronchial epithelia of healthy controls and severe asthma patients were reconstituted in vitro using air-liquid interface culture. Measurements of CD146 expression were made on differentiated epithelium (n = 20 control and 20 severe asthma patients). Then, undifferentiated and differentiated bronchial epithelial cells were sorted based on the expression level of CD146. The sorted undifferentiated bronchial epithelial cells were cultured and monitored during the differentiation process until obtention of a fully differentiated epithelium (n = 3). The sorted differentiated bronchial epithelial cells were used to perform RNA-Seq experiments (n = 4).
Results
We showed that CD146 is highly expressed in severe asthma patients compared to healthy controls both at mRNA and protein levels in differentiated epithelium. Then, we have shown that CD146 expression is not ubiquitous in the differentiated bronchial epithelium. Cell sorting and RNA-seq experiments demonstrated that CD146 is mostly expressed by the basal epithelial cells in the differentiated epithelium. Finally, morphological analysis revealed that CD146 seems to play a role in the bronchial epithelium differentiation process. Indeed, fully differentiated epithelium obtained from CD146+ and CD146− sorted undifferentiated bronchial epithelial cells were different in morphology and cell composition.
Conclusion
Our results suggest that CD146 is only expressed by basal cells of the bronchial epithelium and supports an important role in the differentiation of this epithelium. Moreover, we demonstrated that CD146is overexpressed in severe asthma, suggesting a possible role of this molecule in this disease notably during repair epithelial process.
{"title":"Involvement of epithelial CD146 in severe asthma","authors":"F. Lepretre , L. Moreno , A. Joshkon , N. Bardin , M. Blot-Chabaud , P. Chanez , D. Gras","doi":"10.1016/j.rmr.2025.02.049","DOIUrl":"10.1016/j.rmr.2025.02.049","url":null,"abstract":"<div><h3>Introduction</h3><div>Asthma is a chronic lung disease affecting 300 million people worldwide, 2-10 % of whom suffer from severe asthma. In asthma, the bronchial epithelium is dysregulated, contributing to the pathophysiology of the disease. CD<sub>146</sub> is an adhesion molecule that is highly expressed on all the cells from the vascular system, including endothelial cells. It is also expressed by epithelial cells, but its functions in these cells are poorly understood, as is its role in severe asthma. The aim of our study is to elucidate the role of CD<sub>146</sub> in the bronchial epithelium and its implication in severe asthma.</div></div><div><h3>Methods</h3><div>Bronchial epithelia of healthy controls and severe asthma patients were reconstituted in vitro using air-liquid interface culture. Measurements of CD<sub>146</sub> expression were made on differentiated epithelium (n<!--> <!-->=<!--> <!-->20 control and 20 severe asthma patients). Then, undifferentiated and differentiated bronchial epithelial cells were sorted based on the expression level of CD<sub>146</sub>. The sorted undifferentiated bronchial epithelial cells were cultured and monitored during the differentiation process until obtention of a fully differentiated epithelium (n<!--> <!-->=<!--> <!-->3). The sorted differentiated bronchial epithelial cells were used to perform RNA-Seq experiments (n<!--> <!-->=<!--> <!-->4).</div></div><div><h3>Results</h3><div>We showed that CD<sub>146</sub> is highly expressed in severe asthma patients compared to healthy controls both at mRNA and protein levels in differentiated epithelium. Then, we have shown that CD<sub>146</sub> expression is not ubiquitous in the differentiated bronchial epithelium. Cell sorting and RNA-seq experiments demonstrated that CD<sub>146</sub> is mostly expressed by the basal epithelial cells in the differentiated epithelium. Finally, morphological analysis revealed that CD<sub>146</sub> seems to play a role in the bronchial epithelium differentiation process. Indeed, fully differentiated epithelium obtained from CD<sub>146</sub>+ and CD<sub>146</sub>− sorted undifferentiated bronchial epithelial cells were different in morphology and cell composition.</div></div><div><h3>Conclusion</h3><div>Our results suggest that CD<sub>146</sub> is only expressed by basal cells of the bronchial epithelium and supports an important role in the differentiation of this epithelium. Moreover, we demonstrated that CD<sub>146</sub>is overexpressed in severe asthma, suggesting a possible role of this molecule in this disease notably during repair epithelial process.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 206"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.045
J. Mazenq , L. Moreno , J-C. Dubus , P. Chanez , D. Gras
Introduction
La bronchiolite oblitérante est une pathologie pulmonaire obstructive chronique entraînant l’oblitération des petites voies respiratoires. Il s’agit d’une pathologie rare dont la prévalence et l’incidence sont inconnues en Europe. Elle est secondaire à une infection sévère des voies respiratoires inférieures chez l’enfant dont l’adénovirus est l’agent causal principal. Notre objectif principal est de décrire les atteintes de l’épithélium respiratoire chez les enfants présentant une bronchiolite oblitérante post-infectieuse (PIBO).
Méthodes
Une étude morphologique et fonctionnelle de l’épithélium bronchique d’enfants présentant une PIBO (n = 3) a été réalisée à l’aide d’un modèle d’épithélium reconstitué in vitro en interface air-liquide (ClinicalTrial.gov ID NCT06140901) et comparée à une population contrôle (prélèvement pulmonaire issu d’enfants nécessitant une chirurgie pour malformation pulmonaire (n = 8) (CERC-SFCTCV-2023-11-21_31945). La production de médiateurs pro-inflammatoires et antiviraux susceptibles d’être impliqués dans le développement d’une PIBO a été mesurée (RT-qPCR et ELISA) à l’état basal.
Résultats
Des épithéliums reconstitués in vitro d’enfants présentant une PIBO ont été obtenus avec succès. L’étude de la cohésion cellulaire, indirectement mesurée par résistance électrique transépithéliale (TEER), est identique dans les 2 populations d’étude. Concernant l’activité ciliaire, elle est présente dans les 2 populations d’étude. L’étude des mucines (MUC5AC et MUC5B) au niveau transcrit et protéique ne retrouve pas de différence entre les cellules épithéliales issues de patient présentant une PIBO et les cellules épithéliales de la population contrôle. L’étude des récepteurs à l’adénovirus (CXADR et ICAM-1) au niveau transcrit ne retrouve pas de différence entre les 2 populations d’étude. À l’état basal, les transcrits IL-33 sont significativement plus faibles dans les cellules épithéliales de PIBO et ceux de TSLP semblent plus faiblement exprimés dans la PIBO comparativement à la population contrôle, alors qu’il ne semble pas y avoir de différence avec l’IL-8. Au niveau protéique, la sécrétion de TSLP est significativement plus faible dans les cellules épithéliales de PIBO, comparativement à la population contrôle, alors que l’on ne retrouve pas de différence au niveau de l’IL-8.
Conclusion
Ces résultats préliminaires suggèrent un faible taux d’alarmines chez les enfants atteints de PIBO, ce qui pourrait être la conséquence de leur défaut de réponse à l’infection virale initiale. Il semble important d’évaluer la réponse virale des cellules épithéliales après stimulation par l’adénovirus, pour mieux comprendre l’implication potentielle de l’épithélium respiratoire dans cette pathologie.
支气管炎是一种慢性阻塞性肺病,导致小气道阻塞。这是一种罕见的疾病,其患病率和发病率在欧洲未知。它是儿童严重的下呼吸道感染的继发疾病,腺病毒是主要病因。我们的主要目标是描述感染后强迫性支气管炎(PIBO)儿童的呼吸上皮病变。MéthodesUne研究支气管上皮细胞形态和功能上具有PIBO (n = 3)的儿童进行了模型d’épithélium体外合成的界面,我们提出ClinicalTrial.gov ID NCT06140901比作一个人口)和控制(肺切除后需要手术的儿童为肺畸形(n = 8) (CERC-SFCTCV-2023-11-21_31945)。在基底状态下测量了可能参与PIBO发展的促炎和抗病毒介质(RT-qPCR和ELISA)的产生。成功获得PIBO患儿体外重建上皮。通过上皮电阻抗(TEER)间接测量的细胞内聚研究在两个研究人群中是相同的。关于纤毛活动,它存在于两个研究人群中。在转录和蛋白质水平上对MUC5AC和MUC5B的研究发现,PIBO患者的上皮细胞与对照组的上皮细胞之间没有差异。在转录水平上对腺病毒受体(CXADR和ICAM-1)的研究没有发现两个研究人群之间的差异。在基线状态下,PIBO上皮细胞中的IL-33转录本明显较弱,与对照组相比,PIBO中的TSLP转录本似乎较弱,而IL-8似乎没有差异。在蛋白质水平上,与对照组相比,PIBO上皮细胞中TSLP的分泌明显较低,而IL-8水平没有差异。结论这些初步结果表明,患有PIBO的儿童警报率较低,这可能是由于他们对最初的病毒感染缺乏反应。为了更好地了解呼吸上皮细胞在腺病毒刺激下的潜在参与,评估上皮细胞的病毒反应似乎很重要。
{"title":"Étude pilote morphologique et fonctionnelle de l’épithélium respiratoire des enfants présentant une bronchiolite oblitérante post infectieuse","authors":"J. Mazenq , L. Moreno , J-C. Dubus , P. Chanez , D. Gras","doi":"10.1016/j.rmr.2025.02.045","DOIUrl":"10.1016/j.rmr.2025.02.045","url":null,"abstract":"<div><h3>Introduction</h3><div>La bronchiolite oblitérante est une pathologie pulmonaire obstructive chronique entraînant l’oblitération des petites voies respiratoires. Il s’agit d’une pathologie rare dont la prévalence et l’incidence sont inconnues en Europe. Elle est secondaire à une infection sévère des voies respiratoires inférieures chez l’enfant dont l’<em>adénovirus</em> est l’agent causal principal. Notre objectif principal est de décrire les atteintes de l’épithélium respiratoire chez les enfants présentant une bronchiolite oblitérante post-infectieuse (PIBO).</div></div><div><h3>Méthodes</h3><div>Une étude morphologique et fonctionnelle de l’épithélium bronchique d’enfants présentant une PIBO (n<!--> <!-->=<!--> <!-->3) a été réalisée à l’aide d’un modèle d’épithélium reconstitué <em>in vitro</em> en interface air-liquide (ClinicalTrial.gov ID NCT06140901) et comparée à une population contrôle (prélèvement pulmonaire issu d’enfants nécessitant une chirurgie pour malformation pulmonaire (n<!--> <!-->=<!--> <!-->8) (CERC-SFCTCV-2023-11-21_31945). La production de médiateurs pro-inflammatoires et antiviraux susceptibles d’être impliqués dans le développement d’une PIBO a été mesurée (RT-qPCR et ELISA) à l’état basal.</div></div><div><h3>Résultats</h3><div>Des épithéliums reconstitués <em>in vitro</em> d’enfants présentant une PIBO ont été obtenus avec succès. L’étude de la cohésion cellulaire, indirectement mesurée par résistance électrique transépithéliale (TEER), est identique dans les 2 populations d’étude. Concernant l’activité ciliaire, elle est présente dans les 2 populations d’étude. L’étude des mucines (MUC5AC et MUC5B) au niveau transcrit et protéique ne retrouve pas de différence entre les cellules épithéliales issues de patient présentant une PIBO et les cellules épithéliales de la population contrôle. L’étude des récepteurs à l’<em>adénovirus</em> (CXADR et ICAM-1) au niveau transcrit ne retrouve pas de différence entre les 2 populations d’étude. À l’état basal, les transcrits IL-33 sont significativement plus faibles dans les cellules épithéliales de PIBO et ceux de TSLP semblent plus faiblement exprimés dans la PIBO comparativement à la population contrôle, alors qu’il ne semble pas y avoir de différence avec l’IL-8. Au niveau protéique, la sécrétion de TSLP est significativement plus faible dans les cellules épithéliales de PIBO, comparativement à la population contrôle, alors que l’on ne retrouve pas de différence au niveau de l’IL-8.</div></div><div><h3>Conclusion</h3><div>Ces résultats préliminaires suggèrent un faible taux d’alarmines chez les enfants atteints de PIBO, ce qui pourrait être la conséquence de leur défaut de réponse à l’infection virale initiale. Il semble important d’évaluer la réponse virale des cellules épithéliales après stimulation par l’<em>adénovirus</em>, pour mieux comprendre l’implication potentielle de l’épithélium respiratoire dans cette pathologie.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 204"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01Epub Date: 2025-04-08DOI: 10.1016/j.rmr.2025.02.086
E. Lhospice , G. Hugon , F. Panaro , B. Al Taweel , S. Matecki , G. Carnac
Introduction
The stretch-induced behaviors of myogenic progenitors from the human diaphragm during mechanical ventilation are poorly understood. In all muscles, following injury, quiescent satellite cells (SCs) become activated, proliferate into myoblasts, and then merge and differentiate to form myotubes. Until now, SC adaptation to injury has been considered similar across various muscles. However, in animal models, transcriptional factors involved in maintaining the quiescent state, such as PAX3 and PAX7, are expressed differently between the diaphragm and quadriceps. In humans, no data currently exist to determine whether differences in stretch-induced behavior of myogenic progenitors during mechanical ventilation exist between these two muscles.
Methods
To address this issue, we purified and characterized human satellite cells from quadriceps and diaphragm biopsies from 11 patients. We then plan to culture these cells on a stretchable PDMS support to develop an in vitro model involving mechanical stress applied to human primary muscle-derived cells. A stretch of 12% of the initial length was applied using a FlexCell apparatus at a frequency of 0.3 Hz to mimic mechanical ventilation in the ICU as showed in Fig. 1.
Results
Our preliminary results (n = 6) show that the Pax7/Pax3 ratio at the myoblast stage, the fusion index, and the surface area at the myotube stage were higher in quadriceps compared to the diaphragm, indicating a higher quality of differentiation (Fig. 2). In a preliminary exploratory experiment, human diaphragm muscle cells from one patient were subjected to different stretching protocols, varying between 2 and 6 days, initiated at different stages of development. Our first results as indicated in Fig. 3 show that the quadriceps and diaphragm cells tolerate the stretching protocol and can proliferate and differentiate under these conditions.
Conclusion
Our preliminary results show that a comparative study between diaphragmatic and quadriceps cells will allow us in the future to assess the sensitivity of these two cell populations to mechanical stress.
{"title":"Are the behaviors of myogenic progenitors induced by mechanical stretch similar between the human quadriceps and diaphragm?","authors":"E. Lhospice , G. Hugon , F. Panaro , B. Al Taweel , S. Matecki , G. Carnac","doi":"10.1016/j.rmr.2025.02.086","DOIUrl":"10.1016/j.rmr.2025.02.086","url":null,"abstract":"<div><h3>Introduction</h3><div>The stretch-induced behaviors of myogenic progenitors from the human diaphragm during mechanical ventilation are poorly understood. In all muscles, following injury, quiescent satellite cells (SCs) become activated, proliferate into myoblasts, and then merge and differentiate to form myotubes. Until now, SC adaptation to injury has been considered similar across various muscles. However, in animal models, transcriptional factors involved in maintaining the quiescent state, such as PAX3 and PAX7, are expressed differently between the diaphragm and quadriceps. In humans, no data currently exist to determine whether differences in stretch-induced behavior of myogenic progenitors during mechanical ventilation exist between these two muscles.</div></div><div><h3>Methods</h3><div>To address this issue, we purified and characterized human satellite cells from quadriceps and diaphragm biopsies from 11 patients. We then plan to culture these cells on a stretchable PDMS support to develop an in vitro model involving mechanical stress applied to human primary muscle-derived cells. A stretch of 12% of the initial length was applied using a FlexCell apparatus at a frequency of 0.3<!--> <!-->Hz to mimic mechanical ventilation in the ICU as showed in <span><span>Fig. 1</span></span>.</div></div><div><h3>Results</h3><div>Our preliminary results (<em>n</em> <!-->=<!--> <!-->6) show that the Pax7/Pax3 ratio at the myoblast stage, the fusion index, and the surface area at the myotube stage were higher in quadriceps compared to the diaphragm, indicating a higher quality of differentiation (<span><span>Fig. 2</span></span>). In a preliminary exploratory experiment, human diaphragm muscle cells from one patient were subjected to different stretching protocols, varying between 2 and 6 days, initiated at different stages of development. Our first results as indicated in <span><span>Fig. 3</span></span> show that the quadriceps and diaphragm cells tolerate the stretching protocol and can proliferate and differentiate under these conditions.</div></div><div><h3>Conclusion</h3><div>Our preliminary results show that a comparative study between diaphragmatic and quadriceps cells will allow us in the future to assess the sensitivity of these two cell populations to mechanical stress.</div></div>","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":"42 4","pages":"Page 225"},"PeriodicalIF":0.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}